文献速递肝病

肝硬化中循环单核细胞上调CD52并维持先天免疫功能,除非出现急性失代偿

Circulating monocytes upregulate CD52 and sustain innate immune function in cirrhosis unless acute decompensation emerges.
PubMed 文献 · J Hepatol · 2025-01-14

该研究采用单细胞RNA测序系统分析健康对照与代偿期/非急性失代偿期肝硬化患者循环单核细胞的异质性,发现CD52在单核细胞上的表达随代偿期及非急性失代偿期肝硬化显著升高,CD52高表达单核细胞具有活跃吞噬细胞的功能表型;急性失代偿后PLC升高使CD52被剪切,循环中出现可溶性CD52,CD52低表达免疫抑制性单核细胞占优势与感染及无移植生存率低相关。

要点

  • 单核细胞分为7个簇,其丰度在不同肝硬化阶段间存在差异,证实晚期CD14lowCD16++减少及单核细胞髓系来源抑制细胞出现。
  • CD52在单核细胞上的表达在代偿期及非急性失代偿期肝硬化中显著升高。
  • 急性失代偿后PLC升高使CD52被剪切,循环中可检测到可溶性CD52。

核心结论

  • CD52可能成为未来免疫治疗的生物学相关靶点。
  • 稳定CD52可能增强肝硬化背景下单核细胞功能及感染控制,并以可溶性CD52/PLC作为免疫麻痹的生物标志物进行指导。

研究设计与样本

  • 采用单细胞RNA测序系统研究健康与代偿期/非急性失代偿期肝硬化患者的循环单核细胞,并通过流式细胞术及离体单核细胞多种功能试验确认选择性基因。

主要发现

  • 将单核细胞分为7个簇,其丰度在不同肝硬化阶段间存在差异,证实既往报道的变化,即晚期CD14lowCD16++减少及单核细胞髓系来源抑制细胞出现。
  • 检测到健康与疾病间及不同阶段间的差异表达基因,首次包括CD52;CD52在单核细胞上的表达通过代偿期及非急性失代偿期肝硬化显著增加。
  • 肝硬化患者中CD52highCD14+CD16highHLA-DRhigh单核细胞具有活跃吞噬细胞的功能表型,迁移潜能增强、细胞因子产生能力增加,但激活T细胞的能力有限。
  • 急性失代偿后,CD52被升高的PLC剪切,循环中检测到可溶性CD52;抑制和剪切CD52在离体和体外显著抑制单核细胞功能,而急性失代偿患者中免疫抑制性CD52low循环单核细胞占优势与感染及无移植生存率低相关。

临床怎么用

  • 作者认为CD52可能代表未来免疫治疗的生物学相关靶点。
  • 作者认为稳定CD52可能增强肝硬化背景下单核细胞功能及感染控制,并以可溶性CD52/PLC作为免疫麻痹的生物标志物进行指导。
  • 作者认为表达CD52的单核细胞具有有益的抗微生物功能,CD52稳定化也可能代表一种值得探索的治疗方法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The susceptibility of patients with cirrhosis to infection, a major determinant of prognosis, relates to the development of immuneparesis, a complex interplay of different immunosuppressive cells and soluble factors. The mechanisms underlying the dynamics of immuneparesis of innate immunity remain unclear. We aimed to dissect the heterogeneity of circulating monocyte states in different stages of cirrhosis, and to determine the function of selected differentially expressed genes. METHODS: We systematically investigated circulating monocytes in health and compensated/non-acutely decompensated cirrhosis using single-cell RNA sequencing. Selective genes were confirmed by flow cytometry and diverse functional assays on monocytes ex vivo. RESULTS: We partitioned monocytes into seven clusters. Their abundances varied between cirrhosis stages, confirming previously reported changes, i.e. the reduction in CD14lowCD16++ and emergence of monocytic myeloid-derived suppressor cells in advanced stages. Differentially expressed genes between health and disease and among stages were detected, including CD52 for the first time. CD52 expression on monocytes significantly increased through compensated and non-acutely decompensated cirrhosis. In patients with cirrhosis, CD52highCD14+CD16highHLA-DRhigh monocytes had a functional phenotype of active phagocytes, with enhanced migratory potential and increased cytokine production capacity but limited ability to activate T cells. Following acute decompensation, CD52 was cleaved by elevated PLC, and soluble CD52 was detected in the circulation. Inhibition and cleavage of CD52 significantly suppressed monocyte functions ex vivo and in vitro, while the predominance of immunosuppressive CD52low circulating monocytes in patients with acute decompensation was associated with infection and low transplant-free survival. CONCLUSION: CD52 may represent a biologically relevant target for future immunotherapy. Stabilising CD52 may enhance monocyte functions and infection control in the context of cirrhosis, guided by soluble CD52/PLC as biomarkers of immuneparesis. IMPACT AND IMPLICATIONS: Monocyte dysfunction substantially contributes to infection susceptibility, which is a major determinant of the prognosis of patients with cirrhosis and represents a major unmet therapeutic need. Its underlying mechanisms remain poorly understood, although, among hepatologists, it is thought that the therapeutic reconstitution of monocyte function could enhance defence against infection and thus reduce morbidity and mortality of patients with cirrhosis. By systematically delineating the heterogeneity and function of circulating monocytes ex vivo, we identified that the absence of CD52 expression on monocytes represented a distinct biomarker of monocyte dysfunction in patients with cirrhosis, discriminating patients at substantial risk of infectious complications. Otherwise, given the beneficial antimicrobial functions of CD52-expressing monocytes, CD52 stablisation may also represent a therapeutic approach worth exploring.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Geng A, Brenig RG, Roux J, et al. Circulating monocytes upregulate CD52 and sustain innate immune function in cirrhosis unless acute decompensation emerges. J Hepatol. 2025. PMID: 39818234. doi:10.1016/j.jhep.2024.12.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。